Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-383 bioequivalence study in healthy volunteers
NCT07304700Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone + empagliflozin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Concentration at 48 hours. Started Oct 2025; status: completed.
02
Drugs
lobeglitazone + empagliflozin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07304700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07304700.